To effectively treat and minimize scarring, addressing inflammation must be the primary objective. While acute inflammation is a natural part of the body's initial wound-healing response, prolonged or excessive inflammation is highly damaging. It not only causes surface irritation and discomfort, but it also fundamentally disrupts the skin's aesthetic normalcy and may cause thick, raised, and inflexible scar tissue.
Biomarkers Explained
Advanced scar treatments focus on managing specific biomarkers. Biomarkers are measurable biological molecules—such as proteins or enzymes. By tracking and targeting the specific biomarkers responsible for inflammation, it is possible to actively shift the skin's environment from a state of chronic scarring to one of improved health.
ScarBlast™ is scientifically formulated to address three critical biomarkers that dictate the skin's healing trajectory:
-
SIRT3 (Sirtuin 3): SIRT3 is a vital mitochondrial enzyme that plays a profound role in regulating cellular inflammation and promoting tissue repair. Research shows that when SIRT3 levels are diminished, the skin experiences prolonged, dysregulated inflammation. By addressing and supporting SIRT3 activity, ScarBlast helps control excessive immune responses, protects cells from stress, and encourages efficient, healing without over-scarring.
-
IL-6 (Interleukin-6): IL-6 is a potent pro-inflammatory cytokine. While necessary for the initial immune defense, sustained, high levels of IL-6 are a primary driver of fibrotic diseases and severe scar formation. Overactive IL-6 signals the skin to continuously deposit excess scar tissue. Mitigating IL-6 activity is crucial for stopping the fibrotic cascade and preventing thick, raised scars from taking hold.
-
IL-8 (Interleukin-8): Acting as a chemical messenger for the immune system, IL-8 is a cytokine that constantly recruits inflammatory white blood cells to the site of an injury. When IL-8 remains elevated, the wound site stays trapped in a constant state of inflammation. This delays healing, increases cellular damage, and prevents the skin from returning to normalcy. Regulating IL-8 is essential to calm the immune response and allow the skin to finalize healing.
Conclusion
By actively targeting the SIRT3 pathway and managing the inflammatory cytokines IL-6 and IL-8, ScarBlast™ goes beyond surface-level soothing. It addresses the root cause of scarring, mitigating inflammatory damage and assisting the skin to heal smoothly and naturally.